EA200701986A1 - Улучшенные составы фенофибрата, содержащие ментол или смесь пэг/полоксамера - Google Patents

Улучшенные составы фенофибрата, содержащие ментол или смесь пэг/полоксамера

Info

Publication number
EA200701986A1
EA200701986A1 EA200701986A EA200701986A EA200701986A1 EA 200701986 A1 EA200701986 A1 EA 200701986A1 EA 200701986 A EA200701986 A EA 200701986A EA 200701986 A EA200701986 A EA 200701986A EA 200701986 A1 EA200701986 A1 EA 200701986A1
Authority
EA
Eurasian Patent Office
Prior art keywords
mixture
menthol
surfactants
peg
poloxamer
Prior art date
Application number
EA200701986A
Other languages
English (en)
Inventor
Моше Флашнер-Барак
Е. Ицхак Лернер
Веред Розенбергер
Наоми Молдавски
Original Assignee
Тева Фармасьютикал Индастриес Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тева Фармасьютикал Индастриес Лтд. filed Critical Тева Фармасьютикал Индастриес Лтд.
Publication of EA200701986A1 publication Critical patent/EA200701986A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится по меньшей мере к одной композиции для лечения повышенных уровней триглицеридов, включающей терапевтически эффективное количество фенофибрата или другого фибратсодержащего лекарственного вещества, находящегося в непосредственном контакте с ментолом или со смесью поверхностно-активных веществ, где ментол может быть ментолом или смесью ментола и поверхдостно-активных веществ и где смесь поверхностно-активных веществ может быть смесью полиэтиленгликоля и полоксамера, как например, ПЭГ (1000) и полоксамера (407). Изобретение также относится к способу лечения повышенных уровней триглицеридов у субъекта, включающему введение субъекту композиции, содержащей терапевтически эффективное количество фенофибрата или другого фибратсодержащего лекарственного вещества и ментола или смеси поверхностно-активных веществ, где фенофибрат или другое фибратсодержащее лекарственное вещество находится в непосредственном контакте с ментолом или со смесью поверхностно-активных веществ, где ментол может быть ментолом или смесью ментола и поверхностно-активных веществ, а смесь поверхностно-активных веществ может быть смесью полиэтиленгликоля и полоксамера, как например, ПЭГ (1000) и полоксамера (407).
EA200701986A 2005-03-30 2005-12-29 Улучшенные составы фенофибрата, содержащие ментол или смесь пэг/полоксамера EA200701986A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66619205P 2005-03-30 2005-03-30
PCT/US2005/047676 WO2006107357A1 (en) 2005-03-30 2005-12-29 Improved formulations of fenofibrate containing menthol or a peg/poloxamer mixture

Publications (1)

Publication Number Publication Date
EA200701986A1 true EA200701986A1 (ru) 2008-04-28

Family

ID=35058530

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200701750A EA200701750A1 (ru) 2005-03-30 2005-07-18 Улучшенные составы фенофибрата, содержащие ментол или пэг/полоксамер
EA200701986A EA200701986A1 (ru) 2005-03-30 2005-12-29 Улучшенные составы фенофибрата, содержащие ментол или смесь пэг/полоксамера

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA200701750A EA200701750A1 (ru) 2005-03-30 2005-07-18 Улучшенные составы фенофибрата, содержащие ментол или пэг/полоксамер

Country Status (12)

Country Link
US (1) US20060222706A1 (ru)
EP (2) EP1861084A1 (ru)
JP (2) JP2008505934A (ru)
KR (2) KR20070113289A (ru)
CN (3) CN101212962A (ru)
AU (2) AU2005330266A1 (ru)
BR (2) BRPI0520138A2 (ru)
CA (2) CA2601372A1 (ru)
EA (2) EA200701750A1 (ru)
IL (2) IL185735A0 (ru)
MX (2) MX2007011858A (ru)
WO (2) WO2006107316A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2541382A1 (en) * 2003-10-10 2005-04-21 Lifecycle Pharma A/S A solid dosage form comprising a fibrate and a statin
KR20130103818A (ko) * 2003-10-10 2013-09-24 벨로시스 파마슈티컬스 에이/에스 피브레이트를 포함하는 고형 제제
US9173847B2 (en) * 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
US7569612B1 (en) 2006-08-21 2009-08-04 Mutual Pharmaceutical Company, Inc. Methods of use of fenofibric acid
JP5186159B2 (ja) * 2006-08-31 2013-04-17 あすか製薬株式会社 フェノフィブラート含有組成物
JP2013047282A (ja) * 2006-08-31 2013-03-07 Aska Pharmaceutical Co Ltd フェノフィブラート含有組成物
WO2008104852A2 (en) * 2007-02-26 2008-09-04 Wockhardt Research Centre Pharmaceutical compositions comprising adsorbate of fenofibrate
WO2010033179A1 (en) * 2008-09-17 2010-03-25 Mylan Laboratories, Inc. Granulates, process for preparing them and pharmaceutical products containing them
US8632846B2 (en) * 2010-09-17 2014-01-21 Medtronic Vascular, Inc. Apparatus and methods for loading a drug eluting medical device
CA2857430C (en) 2011-12-14 2019-12-03 Lts Lohmann Therapie-Systeme Ag Wafer and capsule formulations with enhanced dissolution rates for fenofibrate
WO2014091318A1 (en) 2012-12-11 2014-06-19 Lupin Atlantis Holdings, S.A. Reduced dose pharmaceutical compositions of fenofibrate

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
US5545628A (en) * 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
FR2730231B1 (fr) * 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
FR2737121B1 (fr) * 1995-07-27 1997-10-03 Cl Pharma Nouvelles formulations galeniques du fenofibrate et leurs applications
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US6814977B1 (en) * 1998-12-18 2004-11-09 Abbott Laboratories Formulations comprising lipid-regulating agents
US6368622B2 (en) * 1999-01-29 2002-04-09 Abbott Laboratories Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
US6383517B1 (en) * 1999-01-29 2002-05-07 Abbott Laboratories Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
US6719999B2 (en) * 1999-03-31 2004-04-13 Abbott Laboratories Formulations comprising lipid-regulating agents
US6372251B2 (en) * 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
FR2795961B1 (fr) * 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
WO2001034119A2 (en) * 1999-11-12 2001-05-17 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
EP1255565A1 (de) * 2000-01-13 2002-11-13 MERCK PATENT GmbH Pharmazeutische zubereitungen enthaltend 2-pyrrolidon als lösungsvermittler
AU2001262945B2 (en) * 2000-09-20 2006-02-02 Skyepharma Canada Inc. Spray drying process and compositions of fenofibrate
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US6878693B2 (en) * 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
ATE450252T1 (de) * 2002-03-26 2009-12-15 Teva Pharma Arzneimittel-mikroteilchen
US20040005339A1 (en) * 2002-06-28 2004-01-08 Shojaei Amir H. Formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability
CN1882313A (zh) * 2003-02-20 2006-12-20 特瓦制药工业有限公司 药物的薄荷醇溶液
KR20130103818A (ko) * 2003-10-10 2013-09-24 벨로시스 파마슈티컬스 에이/에스 피브레이트를 포함하는 고형 제제
CA2541382A1 (en) * 2003-10-10 2005-04-21 Lifecycle Pharma A/S A solid dosage form comprising a fibrate and a statin
US9173847B2 (en) * 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
US20050096391A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and rosuvastatin
US20050096390A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and pravastatin
WO2006037348A1 (en) * 2004-10-01 2006-04-13 Lifecycle Pharma A/S Pharmaceutical compositions comprising fenofibrate and a statin

Also Published As

Publication number Publication date
JP2008534584A (ja) 2008-08-28
MX2007011858A (es) 2008-03-25
EP1707196A1 (en) 2006-10-04
KR20070113289A (ko) 2007-11-28
KR20070120990A (ko) 2007-12-26
WO2006107357A1 (en) 2006-10-12
CA2601372A1 (en) 2006-10-12
US20060222706A1 (en) 2006-10-05
WO2006107316A8 (en) 2007-11-22
MX2007012125A (es) 2007-12-07
AU2005330320A1 (en) 2006-10-12
CN101217950A (zh) 2008-07-09
CA2601374A1 (en) 2006-10-12
CN101212962A (zh) 2008-07-02
IL185734A0 (en) 2008-01-06
WO2006107316A1 (en) 2006-10-12
IL185735A0 (en) 2008-01-06
EP1861084A1 (en) 2007-12-05
BRPI0520138A2 (pt) 2011-04-19
JP2008505934A (ja) 2008-02-28
EA200701750A1 (ru) 2008-02-28
AU2005330266A1 (en) 2006-10-12
CN101217951A (zh) 2008-07-09
BRPI0520167A2 (pt) 2009-04-22

Similar Documents

Publication Publication Date Title
EA200701986A1 (ru) Улучшенные составы фенофибрата, содержащие ментол или смесь пэг/полоксамера
EA200701751A1 (ru) Улучшенные составы фенофибрата
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
BR0313343A (pt) Uso de uma mistura de agentes permeantes, soluções para aplicação ungueal e periungueal e uso de uma solução para aplicação ungueal e periungueal
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
ATE544866T1 (de) Adamts13-haltige zusammensetzungen mit thrombolytischer wirkung
EA200800161A1 (ru) Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций
DK1663194T3 (da) Anvendelse af SAHA til behandling af mesotheliom
EA200601776A1 (ru) Метадоновые композиции местного действия и способы их применения
ATE257386T1 (de) Pharmazeutische zusammensetzungen enthaltend eine mischung von selbstvernetzter und nichtselbstvernetzter hyaluronsäure zur behandlung von arthropathien
JO3598B1 (ar) الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
EA200001125A1 (ru) Гелеобразные фармацевтические композиции
ES2091441T3 (es) Composicion farmaceutica.
PE20080331A1 (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
MA30768B1 (fr) Methodes d'administration d'agents hypoglycemiques a longue duree d'action
CO6190598A2 (es) Composiciones farmaceuticas y metodo para el tratamiento de la inflamacion en el ganado y en otros animales
MA29269B1 (fr) Nouvelles compositions ophtalmologiques et leur mode d'utilisation
DE602004017705D1 (de) Zusammensetzungen mit alphahydroxy-säureester zur wirkstofffreisetzung und anwendungsverfahren dafür
PE20061077A1 (es) Composicion farmaceutica que comprende 7-terbutoxi-imino-metil-camptotecina
AR003589A1 (es) Utilizacion de una cantidad eficaz de al menos un peptido en una composicion cosmetica o para la preparacion de un medicamento destinada paratratar la inflamacion, y un procedimiento de tratamiento cosmetico mediante una composicion cosmetica que contiene a dicho peptido.
MX9400800A (es) Un complejo de estabilizacion neutro para ci-979 hci, un activador de la cognicion.
EA200201044A1 (ru) Фармацевтическая композиция с контролируемым высвобождением, содержащая мидодрин и/или десглимидодрин
ECSP045110A (es) Composiciones de la preparación que contiene un compuesto fisiologicamente activo de acidos inestables y procesos para su producción
AR044660A1 (es) Composiciones farmaceuticas de atorvastatina
EA201391063A1 (ru) Аполипопротеин a-iv в качестве антидиабетического пептида